Q3 2022 Axsome Therapeutics Inc Earnings Call
Speaker 1: Perhaps you're muted and I can't hear you.
Nick Pizzie: The facility with Hercules Capital is sufficient to fund anticipated operations into 2025 based on our current operating plan. I will now turn the call over to Lori for a commercial update.
Speaker 1: The next available conference specialist will be with you momentarily.
Lori Englebert: Thank you, Nick, and good morning, everyone. With Cenoci and the very recent launch of Abelity, we now have two marketed products, both of which address serious conditions. I am excited to provide a commercial update for these two important and differentiated therapies. I'd first like to start with Sinoci. Q3 represents the first full quarter for Sinoci as an Axon product. As a reminder, Sinoci is the first and only DNRI for excessive daytime sleepiness and obstructive sleep apnea and narcolepsy, and the first and only wake-promoting agent proven to improve wakefulness for nine hours. In the quarter, total Cinesse prescription growth outpaced the weight-promoting or WPA market.